Ampio Pharmaceuticals to List on the NYSE MKT

                Ampio Pharmaceuticals to List on the NYSE MKT

PR Newswire

GREENWOOD VILLAGE, Colo., June 6, 2013

GREENWOOD VILLAGE, Colo., June 6, 2013 /PRNewswire/ --Ampio Pharmaceuticals,
Inc. (NASDAQ: AMPE) announced today that it has received authorization from
the NYSE Euronext (NYSE MKT) to transfer the listing from the NASDAQ Capital
Market (NASDAQ).

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

The Company expects its common stock to begin trading on the NYSE MKT on
Monday, June 17, under its current ticker symbol, AMPE, and it will celebrate
the transfer of its listing by ringing the opening bell at the New York Stock
Exchange that morning. The company expects to continue to trade on NASDAQ
until the transfer is complete.

Michael Macaluso, Chairman and CEO of Ampio, commented "We are very pleased to
join other strong and growing life science companies on the NYSE community. We
feel that transferring the listing of our common stock to NYSE MKT will result
in better visibility to the financial and medical community, while improving
our liquidity and decreasing our volatility."

"We welcome Ampio Pharmaceuticals to the NYSE community family of listed
companies," said Scott Cutler, Executive Vice President, Global Listings at
NYSE Euronext. "Ampio will be joining other growth oriented companies that
have chosen our advanced and innovative market model to offer a premier venue
for the listing and trading of their stock. We look forward to our
partnership with Ampio and its shareholders."

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that
relate to future plans or events are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of words such as
"believe," "expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include risks associated with clinical trials,
expected results, regulatory approvals, and changes in business conditions and
similar events. The risks and uncertainties involved include those detailed
from time to time in Ampio's filings with the Securities and Exchange
Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com

SOURCE Ampio Pharmaceuticals, Inc.

Website: http://www.ampiopharma.com